Overview
Jose Mendoza is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Mendoza is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Familial Colorectal Cancer. Dr. Mendoza is currently accepting new patients.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
10710 Charter Dr, Suite G020, Columbia, MD 21044
8926 Woodyard Rd, Clinton, MD 20735
Medstar Medical Group Ii LLC
Claudine Isaacs is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Isaacs is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy.
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.
Medical Faculty Associates, Inc
Pavani Chalasani is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Chalasani is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Chalasani is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- AnemiaDr. Mendoza isDistinguished. Learn about Anemia.
- Breast CancerDr. Mendoza isDistinguished. Learn about Breast Cancer.
- Childhood Iron Deficiency AnemiaDr. Mendoza isDistinguished. Learn about Childhood Iron Deficiency Anemia.
- Colorectal CancerDr. Mendoza isDistinguished. Learn about Colorectal Cancer.
- Deep Vein ThrombosisDr. Mendoza isDistinguished. Learn about Deep Vein Thrombosis.
- Familial Colorectal CancerDr. Mendoza isDistinguished. Learn about Familial Colorectal Cancer.
- Advanced
- Adult Soft Tissue SarcomaDr. Mendoza isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- AgranulocytosisDr. Mendoza isAdvanced. Learn about Agranulocytosis.
- ALK-Positive Non-Small Cell Lung Cancer
- Alpha ThalassemiaDr. Mendoza isAdvanced. Learn about Alpha Thalassemia.
- Alpha Thalassemia X-Linked Intellectual Disability Syndrome
- AngiosarcomaDr. Mendoza isAdvanced. Learn about Angiosarcoma.
- Experienced
- Acquired AgranulocytosisDr. Mendoza isExperienced. Learn about Acquired Agranulocytosis.
- Acute Monoblastic Leukemia (AmoL)Dr. Mendoza isExperienced. Learn about Acute Monoblastic Leukemia (AmoL).
- Acute Mountain SicknessDr. Mendoza isExperienced. Learn about Acute Mountain Sickness.
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Mendoza isExperienced. Learn about Acute Myeloid Leukemia (AML).

